A data analyst does not open a dosage question by asking “how much.” She opens it by asking “how good is the evidence for any number at all.” Applied to sermorelin, that second question turns out to be more interesting than the first, because the honest answer is: not very good, and the study most people would recognize as the “big one” belongs to a different drug entirely.
This piece scores the actual published dosing evidence against five criteria, then reports the score. No dose recommendation follows, because none of the studies below license one for the population most people asking this question actually belong to.
The rubric
Five columns, applied consistently to every study cited on this page:
- Sample and population. Small, medium, large. Who was studied.
- Recency. When the trial ran.
- Molecule match. Is this actually sermorelin, or a different GHRH-family compound being borrowed for its numbers.
- Schedule tested. Once nightly, twice daily, something else.
- Endpoint durability. Did the measured benefit hold up, or spike and fade.
A study can score well on four of five and still be useless for setting a sermorelin dose if it fails the molecule-match column. That single failure mode is, as it turns out, the most common trap in consumer dosage guides.
Scoring the actual studies
Corpas et al., 1992, Journal of Clinical Endocrinology and Metabolism [P1]. Sample: small, healthy old men. Recency: 1992, decades old. Molecule match: yes, GHRH(1-29) is sermorelin. Schedule: twice daily. Endpoint: reversed the age-related decline in growth hormone and IGF-1. Verdict: the cleanest hormonal result in the entire dataset, and it used the less convenient, twice-a-day schedule.
Vittone et al., 1997, Metabolism [P2]. Sample: small, healthy elderly men. Recency: 1997. Molecule match: yes. Schedule: once nightly, the schedule almost every online guide recommends. Endpoint: nocturnal growth hormone rose and some strength and endurance measures improved, but IGF-1 was not sustained and body composition did not change. The authors’ own conclusion: single nightly dosing is less effective than multiple daily doses. Verdict: this is the study behind the most commonly sold protocol, and it is the study that undercuts that protocol.
Khorram et al., 1997, Journal of Clinical Endocrinology and Metabolism [P3]. Sample: small, aging men and women. Molecule match: a GHRH(1-29) analog, close enough to count. Endpoint: IGF-1 rose, some immune-marker changes appeared. Verdict: a supporting data point, not a dosing trial in its own right. It neither confirms nor rebuts the frequency finding above.
Baker, Vitiello et al., 2012, Archives of Neurology [P4]. Sample: 152 older adults, the largest and best-designed trial in this entire reference list. Recency: 2012, modern by comparison. Schedule: daily, 20 weeks. Endpoint: improved cognition, IGF-1 up 117%, body fat down 7.4%, both durable over the trial period. On four of five criteria this is the strongest entry on the page. Molecule match: fails. It is tesamorelin, a stabilized, longer-acting GHRH analog, not sermorelin. A longer half-life changes the dosing math on its own terms. Verdict: disqualified for sermorelin purposes, full stop. Any page that quotes these numbers next to the word “sermorelin” is quietly swapping drugs.
Total picture: three small, old sermorelin-relevant trials, one large modern trial that does not actually apply. That is the entire load-bearing evidence base behind every confident “take this much sermorelin” claim you will read elsewhere.
The one finding that survives the scoring
Strip away the weak sample sizes and the age of the data, and one result holds up across the rubric: schedule outperforms convenience. The twice-daily protocol [P1] produced the cleanest, most sustained result. The once-nightly protocol [P2], the one that is easiest to market because it is one shot before bed, produced a weaker effect that did not hold. Sermorelin clears the body quickly and the growth hormone pulse it triggers rises and fades within an hour or two [P6], which is consistent with why one pulse a night underperforms several. That is a real finding about pharmacology, not a stylistic preference, and it is the single most useful thing a dosing page can tell you.
Why no number gets a passing grade
Score any specific “X micrograms nightly is optimal” claim against the rubric above and it fails on recency, on population match (most such claims target anti-aging or body-composition users, not the older, mostly clinical-deficiency subjects in [P1], [P2], [P3]), and often on molecule match if it has quietly borrowed tesamorelin’s numbers. There is no modern, dose-ranging trial in the population most readers belong to. What exists instead is old data plus clinical practice, and clinical practice is not a number a webpage can responsibly print, because it depends on variables a page cannot see: age, health history, current medications, tolerance, and whether stimulating the growth hormone axis is appropriate for that person at all.
That is not a hedge. It is the actual state of the evidence, scored honestly.
Safety notes that interact with the scoring, not separate from it
Reported side effects skew mild: injection-site redness or swelling, flushing, headache, occasional dizziness [P6]. Injection-site effects scale with frequency, which is one more reason the twice-daily-versus-once-nightly question is not a footnote.
There is a genuine structural point in sermorelin’s favor. Because it works by prompting the pituitary rather than replacing hormone directly, the body’s own feedback brakes stay active, making it harder to overdose into the range raw HGH can reach [P6]. That is a real advantage. It scores as a point in sermorelin’s favor on a safety column this rubric did not formally include. It is not, however, a passing grade for self-dosing; appropriateness and interactions still require an individual evaluation.
One more data point that does not move with dose at all: sermorelin sits on the World Anti-Doping Agency’s Prohibited List as a growth hormone-releasing factor [P7]. For a tested athlete, every dose fails that particular test, because the disqualifying variable is the substance, not the amount.
Where the actual number gets set
Since the rubric above disqualifies any static online figure, the number has to come from somewhere else: a supervised clinical relationship where a licensed clinician reviews history, sets a starting protocol, and adjusts it against monitored IGF-1 and symptom response over time. FormBlends operates on that model, a licensed clinician setting and revising the dose, a licensed compounding pharmacy preparing it, rather than a vial arriving with a generic instruction card. That is a description of how the process is structured, not an endorsement of a product to buy, and there is nothing here to add to a cart.
If you’re on a supervised protocol, a simple log of dose, timing, and effects, such as the kind kept in the FormBlends tracker app, gives a clinician actual data to score at your next check-in instead of a memory. It is a logging tool. It does not prescribe anything and there is no checkout attached to it.
Bottom line, scored
Three small, old sermorelin studies and one large modern trial that turns out to be about a different drug. The twice-daily schedule scores best on durability of effect [P1]. The once-nightly schedule most guides sell scores worst, by its own authors’ admission [P2]. Tesamorelin’s numbers [P4] are the best data on the page and the least applicable. No entry earns a passing grade for “here is your dose.” That grade belongs to a clinician who can see your chart, not a webpage that cannot.
See also: 5 Easy Tips to Grow Your Business Network
The usual questions
Why doesn’t this page just give a number of units to inject? Because no number clears the rubric above. The human dosing evidence is small, decades old, and drawn mostly from older adults in the 1990s [P5], so any “ideal dose” printed online is an extrapolation dressed up as a finding. The right dose also depends on age, health history, goals, other medications, and tolerance, variables a page cannot score and a clinician can.
Is once-nightly dosing the best schedule for sermorelin? No, and it’s the finding most guides quietly skip. The 1997 Vittone study found single nightly injections raised nocturnal growth hormone but did not sustain IGF-1 or change body composition, and the authors concluded that single nightly dosing is less effective than multiple daily doses [P2]. The twice-daily protocol produced the cleanest result on record [P1].
Why would dosing more often outscore a single larger dose? Sermorelin clears quickly, and the growth hormone pulse it triggers rises and fades within an hour or two [P6]. One nightly dose produces one short pulse; your natural rhythm runs on multiple pulses, which is closer to what the twice-daily study used [P1]. Frequency appears to matter as much as amount for sustaining IGF-1 [P2].
Can tesamorelin’s dose or results be used as a sermorelin protocol? No, and this is the single easiest scoring error to make. The strongest modern GHRH trial, Baker and Vitiello’s 2012 study showing IGF-1 up 117% and body fat down 7.4%, tested tesamorelin, a different, longer-acting molecule, not sermorelin [P4]. Longer-acting analogs behave differently in the body, so importing that trial’s numbers into a sermorelin protocol fails the molecule-match test outright.
Can you overdose on sermorelin? It’s harder than with raw HGH, because sermorelin works through the pituitary and the body’s own feedback brakes stay active [P6]. That’s a genuine point in its favor, but it doesn’t clear self-dosing for a passing grade, since interactions and appropriateness still depend on an individual evaluation a website cannot perform.
Where should the actual dose get set? In a supervised clinical relationship. A licensed clinician can review history, set a starting protocol, and track IGF-1 and symptom response over time, adjusting as needed, none of which a fixed number on a page can do.
What is sermorelin and how does it differ from HGH injections?
Sermorelin is a synthetic peptide that mimics growth hormone-releasing hormone, prompting the pituitary to produce its own growth hormone rather than replacing it directly. The pituitary still controls output, which keeps natural feedback loops intact. HGH injections bypass that system entirely. Most clinicians count the indirect mechanism as a safety advantage, though head-to-head long-term comparison data remain limited.
How much sermorelin per day is typically prescribed?
Most prescribing protocols fall somewhere between 200 and 500 micrograms injected subcutaneously once daily, usually at bedtime to align with the body’s natural growth hormone pulse. Some providers adjust the dose against IGF-1 lab values rather than a fixed figure. No single dose is universally validated, so the right amount depends on bloodwork, age, and clinical response, not a one-size-fits-all number.
Is sermorelin FDA approved, and does that affect how it is prescribed?
Sermorelin acetate was FDA approved under the brand name Geref for pediatric growth hormone deficiency, but that approval lapsed in 2008 when the manufacturer discontinued the product for business reasons, not safety concerns. Today it is prescribed as a compounded medication through licensed pharmacies, which is legal but means each batch isn’t individually FDA reviewed. A physician-supervised compounding pharmacy, like FormBlends, adds a layer of accountability that unregulated online sources don’t offer.
Does sermorelin actually increase testosterone levels?
Sermorelin doesn’t directly stimulate testosterone production. It targets the growth hormone axis, not the hypothalamic-pituitary-gonadal axis that governs testosterone. Some men report improved energy or libido, which may reflect better sleep or general metabolic improvement from higher IGF-1, but the evidence linking sermorelin to meaningful testosterone increases is thin. Low testosterone as a primary concern usually warrants its own separate evaluation.
References
- Twice-daily GHRH(1-29), which is sermorelin, reversed age-related declines in growth hormone and IGF-1 in healthy old men. Journal of Clinical Endocrinology and Metabolism, 1992. https://pubmed.ncbi.nlm.nih.gov/1379256/
- Single nightly injections of GHRH(1-29) in healthy elderly men increased nocturnal growth hormone release and improved some strength and endurance measures, but did not sustain IGF-1 increases or change body composition; the authors concluded single nightly dosing is less effective than multiple daily doses. Metabolism, 1997. https://pubmed.ncbi.nlm.nih.gov/9005976/
- A GHRH(1-29) analog raised IGF-1 and was associated with immune-marker changes in aging men and women. Journal of Clinical Endocrinology and Metabolism, 1997.
- Controlled trial of tesamorelin (a stabilized GHRH analog, not sermorelin) in 152 older adults over 20 weeks: improved cognition, IGF-1 up 117%, body fat down 7.4%. Archives of Neurology, 2012.
- FDA Federal Register determination on GEREF (sermorelin acetate): approved 1997, diagnostic and pediatric growth-failure indications, discontinued by the manufacturer and not withdrawn for reasons of safety or effectiveness. Federal Register, 2013.
- Sermorelin structure, GHRH-receptor mechanism, rapid clearance and pulsatile GH release, and general reported side-effect profile. Sermorelin overview, Wikipedia.
- Sermorelin listed as a prohibited growth hormone-releasing factor under the WADA Prohibited List. World Anti-Doping Agency, 2026.
